Skip to main content
Premium Trial:

Request an Annual Quote

Venter Institute, Real Time Genomics Ink Stem Cell Research Pact

NEW YORK (GenomeWeb News) – Real Time Genomics and the J. Craig Venter Institute have forged a long-term research pact focused on analyzing the genetic mutations that induced pluripotent stem cells acquire during differentiation, RTG said today.

The partners also will work on identifying and validating human variant information using the Venter human reference diploid genome and associated orthogonal information. They plan to deposit this information in public databases where it can be accessed and used by the life sciences community.

Researchers from both organizations will use RTG's platform and JCVI's infrastructure to identify single nucleotide polymorphisms, insertions and deletions, structural variants, and de novo mutations in data collected from both projects.

"The stem cell collaboration with JCVI is an exciting opportunity to move our technology into new areas as cell lineage progression studies are becoming important in a wide range of" next-generation sequencing applications, Francisco De La Vega, RTG's VP of genome sciences, said in a statement.

He also said that the collaboration affords an opportunity to create standard datasets that can serve as yardstick for measuring the accuracy of other sequencing data and results.

"Because JCVI has considerable orthogonal information related to the Venter reference genome, including Sanger long-read sequence data, data from multiple next-generation sequencing platforms, and even RNAseq data and full phasing information, there is an opportunity to contribute a standard back to the community to improve the sensitivity and specificity of human disease applications using NGS," he said.

Mark Adams, JCVI's scientific director, noted that a better understanding of iPSC mutations would have implications for their use in developing new therapies.

"These mutations might affect how iPSCs behave as disease models and could limit the therapeutic use of these cells, but there are many pitfalls in analyzing sequence data to locate and interpret these rare mutations," he said.

At JCVI, "we have built a significant dataset around this genome and want to help others leverage the information to improve their own research," he added.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.